The chemical class known as TAF1L Inhibitors comprises a group of compounds meticulously designed to selectively target the molecular entity TAF1L. TAF1L, or TATA-Box Binding Protein Associated Factor 1-Like, is a member of the TAF family involved in the assembly and functioning of the RNA polymerase II transcription initiation complex. This complex is pivotal for initiating the transcription of protein-coding genes in eukaryotic cells. While TAF1L's role in transcriptional regulation is acknowledged, the specific functions and interactions within this context remain subjects of active investigation. Inhibitors within the TAF1L Inhibitors class are intricately engineered molecules with the primary objective of modulating the activity or function of TAF1L, thereby inducing an inhibitory effect. Researchers engaged in this field utilize a multifaceted approach, integrating insights from structural biology, medicinal chemistry, and computational modeling to unravel the complex molecular interactions between the inhibitors and the target TAF1L.
Structurally, TAF1L Inhibitors are characterized by specific molecular features designed to facilitate selective binding to TAF1L. This selectivity is crucial to minimize unintended effects on other cellular components, ensuring a focused impact on the intended molecular target. The development of inhibitors within this chemical class involves a comprehensive exploration of structure-activity relationships, optimization of pharmacokinetic properties, and a deep understanding of the molecular mechanisms associated with TAF1L. As researchers delve deeper into the functional aspects of TAF1L Inhibitors, the knowledge generated contributes not only to deciphering the specific roles of TAF1L but also to advancing our broader comprehension of the intricate processes governing gene expression and transcriptional regulation within cells. The exploration of TAF1L Inhibitors stands as a significant avenue for expanding fundamental knowledge in molecular pharmacology and cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
A macrolide compound that inhibits mTOR, a key regulator of protein synthesis and cell growth, potentially affecting TAF1L expression indirectly. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, thus potentially reducing TAF1L levels post-transcriptionally. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Glucocorticoid receptor antagonist that may alter transcription factor activity, potentially affecting TAF1L expression indirectly. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
A CDK inhibitor that can inhibit transcription elongation by RNA polymerase II, possibly leading to reduced TAF1L mRNA synthesis. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
A diterpene triepoxide that inhibits the activity of RNA polymerase I, II, and III, thus could decrease the transcription of TAF1L. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Binds to DNA and inhibits RNA polymerase movement, potentially decreasing TAF1L transcription. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Disrupts the structure of p300 and CREB binding protein (CBP), which are histone acetyltransferases involved in the regulation of transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that can cause DNA hypomethylation and potentially affect gene expression, including TAF1L. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
A histone deacetylase inhibitor that can change gene expression by affecting chromatin structure and access of transcription machinery. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor which can arrest cell cycle progression and influence transcription factor activity and gene expression. | ||||||